GSK's Nucala gets third approval in China
3rd Jan 2025 07:12
(Sharecast News) - GSK announced on Friday that its monoclonal antibody 'Nucala', or mepolizumab, has received approval from China's National Medical Products Administration for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
Read moreGSK reports positive results from ovarian cancer drug trial
20th Dec 2024 07:12
(Sharecast News) - GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival.
Read moreEU recommends expanding use of GSK endometrial cancer drug
16th Dec 2024 07:04
(Sharecast News) - GSK said the European Union's Committee for Medicinal Products for Human Use has recommended expanding approval of Jemperli in combination with chemotherapy for treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Read moreGSK says US agrees to look at data for new use of COPD drug
9th Dec 2024 07:06
(Sharecast News) - GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new use of its Nucala drug as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Read moreGSK extends strategic vaccine collaboration with Zhifei
5th Dec 2024 09:37
(Sharecast News) - Drugmaker GSK has revised and extended its strategic vaccine collaboration with Chinese firm Chongqing Zhifei Biological Products.
Read moreBerenberg lowers target price on GSK
2nd Dec 2024 11:36
(Sharecast News) - Analysts at Berenberg lowered their target price on drugmaker GSK from £18.20 to £16.00 on Monday after hosting chief financial officer Julie Brown at its 2024 Pharma CFO series.
Read moreGSK's liquid meningitis vaccine approved by EU regulators
27th Nov 2024 07:18
(Sharecast News) - GSK's liquid meningitis vaccine Menveo has been approved by EU regulators, paving the way for a simpler vaccination process against invasive meningococcal disease (IMD).
Read moreGSK's liquid meningitis vaccine approved by EU regulators
27th Nov 2024 07:18
(Sharecast News) - GSK's liquid meningitis vaccine Menveo has been approved by EU regulators, paving the way for a simpler vaccination process against invasive meningococcal disease (IMD).
Read moreGSK's Blenrep treatment accepted for review by FDA
25th Nov 2024 07:55
(Sharecast News) - Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed or refractory multiple myeloma.
Read moreGSK's Arexvy approved for wider age range in Japan
22nd Nov 2024 07:17
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider age range.
Read moreGSK's linerixibat meets primary endpoint
19th Nov 2024 09:21
(Sharecast News) - Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus in primary biliary cholangitis.
Read moreLondon close: Stocks end turbulent week in the red
15th Nov 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
Read moreGSK's Blenrep shows strong survival benefit in myeloma study
14th Nov 2024 07:26
(Sharecast News) - GSK reported positive results from its phase three 'DREAMM-7' trial on Thursday, highlighting a significant overall survival benefit for 'Blenrep', or belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
Read moreLondon close: Stocks mixed as Chancellor unveils tax hikes
30th Oct 2024 14:57
(Sharecast News) - London stocks saw mixed results on Wednesday as investors weighed the impact of the £40bn worth of tax rises announced by Rachel Reeves in her first Budget as Chancellor.
Read moreGSK maintains guidance after mixed third quarter
30th Oct 2024 07:19
(Sharecast News) - GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset weaker sales in vaccines.
Read more